China National Accord Medicines Management
Management criteria checks 3/4
We currently do not have sufficient information about the CEO.
Key information
Zhaoxiong Lin
Chief executive officer
CN¥2.6m
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | 8.8yrs |
| CEO ownership | n/a |
| Management average tenure | 5.5yrs |
| Board average tenure | 3.8yrs |
Recent management updates
Recent updates
Lacklustre Performance Is Driving China National Accord Medicines Corporation Ltd.'s (SZSE:000028) Low P/E
Nov 18
China National Accord Medicines Corporation Ltd. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
Oct 30China National Accord Medicines (SZSE:000028) Seems To Use Debt Quite Sensibly
Oct 10China National Accord Medicines Corporation Ltd.'s (SZSE:000028) Low P/E No Reason For Excitement
Aug 13Estimating The Intrinsic Value Of China National Accord Medicines Corporation Ltd. (SZSE:000028)
Jul 12Is China National Accord Medicines (SZSE:000028) A Risky Investment?
Jun 12Improved Earnings Required Before China National Accord Medicines Corporation Ltd. (SZSE:000028) Shares Find Their Feet
May 12Analysts Are Updating Their China National Accord Medicines Corporation Ltd. (SZSE:000028) Estimates After Its Full-Year Results
Apr 10China National Accord Medicines Corporation Ltd. (SZSE:000028) Shares Could Be 28% Below Their Intrinsic Value Estimate
Mar 15China National Accord Medicines (SZSE:000028) Has A Rock Solid Balance Sheet
Feb 29CEO
Zhaoxiong Lin (57 yo)
8.8yrs
Tenure
CN¥2,550,000
Compensation
Mr. Zhaoxiong Lin, MBA has been General Manager of Sinopharm Medicine Holding Guangzhou Co., Ltd since December 2006. Mr. Lin has been General Manager of China National Accord Medicines Corporation Ltd. si...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| GM & Non-Independent Director | 8.8yrs | CN¥2.55m | no data | |
| Deputy GM | 4.6yrs | CN¥1.66m | no data | |
| General Counsel | 6.3yrs | CN¥1.79m | no data | |
| Deputy GM & Board Secretary | less than a year | no data | no data | |
| Deputy General Manager | no data | CN¥1.66m | 0.00062% CN¥ 96.0k |
5.5yrs
Average Tenure
56yo
Average Age
Experienced Management: 000028's management team is seasoned and experienced (5.5 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| GM & Non-Independent Director | 8.7yrs | CN¥2.55m | no data | |
| Director | 7.9yrs | no data | no data | |
| Non-Independent Director | less than a year | no data | no data | |
| Chairman of the board | 4.1yrs | no data | no data | |
| Chairman of the Board of Supervisors | 5.6yrs | no data | no data | |
| Independent Director | 5.9yrs | CN¥250.00k | no data | |
| Employee Supervisor | 6.3yrs | no data | no data | |
| Non-Independent Director | 3.5yrs | no data | no data | |
| Independent Director | less than a year | no data | no data | |
| Independent Director | less than a year | no data | no data | |
| Supervisor | less than a year | no data | no data | |
| Independent Director | less than a year | no data | no data |
3.8yrs
Average Tenure
54yo
Average Age
Experienced Board: 000028's board of directors are considered experienced (3.8 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 02:34 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
China National Accord Medicines Corporation Ltd. is covered by 27 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Lei Tian | AJ Securities Co., Ltd |
| Shuchang Liu | Changjiang Securities Co. LTD. |
| Yanyin Zhu | China International Capital Corporation Limited |